| Identification | Back Directory | [Name]
N-[4-(6-Fluoro-3,4-dihydro-2(1H)-isoquinolinyl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide | [CAS]
1009344-33-5 | [Synonyms]
KCNQ2/3 activator-1
N-[4-(6-Fluoro-3,4-dihydro-2(1H)-isoquinolinyl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide
Butanamide, N-[4-(6-fluoro-3,4-dihydro-2(1H)-isoquinolinyl)-2,6-dimethylphenyl]-3,3-dimethyl-
KCNQ2/3 activator-1,activator,Potassium Channel,KCNQ2/3,KCNQ2/3 activator 1,KcsA,inhibit,pain,Inhibitor,KCNQ2/3 activator1,KCNQ-2/3 activator-1 | [Molecular Formula]
C23H29FN2O | [MOL File]
1009344-33-5.mol | [Molecular Weight]
368.49 |
| Chemical Properties | Back Directory | [Boiling point ]
541.8±50.0 °C(Predicted) | [density ]
1.125±0.06 g/cm3 (20 ºC 760 Torr) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 50 mg/mL (135.69 mM; Need ultrasonic) | [form ]
Solid | [pka]
14.59±0.70(Predicted) | [color ]
Off-white to gray | [InChI]
InChI=1S/C23H29FN2O/c1-15-10-20(11-16(2)22(15)25-21(27)13-23(3,4)5)26-9-8-17-12-19(24)7-6-18(17)14-26/h6-7,10-12H,8-9,13-14H2,1-5H3,(H,25,27) | [InChIKey]
FJNPZKZPWVVSON-UHFFFAOYSA-N | [SMILES]
C(NC1=C(C)C=C(N2CCC3=C(C2)C=CC(F)=C3)C=C1C)(=O)CC(C)(C)C |
| Hazard Information | Back Directory | [Uses]
KCNQ2/3 activator-1 is an activator of Kv7.2/Kv7.3 (KCNQ2/3) potassium channel. KCNQ2/3 activator-1 has the potential in relieving pain (the main problem from medical treatment) (extracted from patent WO2021113757A1, compound A)[1]. | [References]
[1] Bialer M, et al. Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). I. Drugs in preclinical and early clinical development. Epilepsia. 2020 Nov;61(11):2340-2364. DOI:10.1111/epi.16725
[2] Bialer M, et al. Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). I. Drugs in preclinical and early clinical development. Epilepsia. 2018 Oct;59(10):1811-1841. DOI:10.1111/epi.14557 |
|
|